Exploring the Influence of Health Insurance Plans on Biosimilar Adoption Rates

Files

s41669-023-00447-6.pdf (476.31 KB)

Links to Files

https://link.springer.com/article/10.1007/s41669-023-00447-6

Permanent Link

https://doi.org/10.1007/s41669-023-00447-6
 http://hdl.handle.net/11603/30862

Collections

A. All Hilltop Institute (UMBC) Works
UMBC Faculty Collection

Author/Creator

Author/Creator ORCID

https://orcid.org/0000-0002-6999-7588

Date

2023-11-03

Type of Work

journal articles
Text

Department

Program

Citation of Original Publication

Costin, Jeremy, Morgane C. Mouslim, Mariana P. Socal, and Antonio Trujillo. “Exploring the Influence of Health Insurance Plans on Biosimilar Adoption Rates.” PharmacoEconomics - Open, November 3, 2023. https://doi.org/10.1007/s41669-023-00447-6.

Rights

This item is likely protected under Title 17 of the U.S. Copyright Law. Unless on a Creative Commons license, for uses protected by Copyright Law, contact the copyright holder or the author.
Attribution-NonCommercial 4.0 International (CC BY-NC 4.0 DEED)

Subjects

Abstract

Background: We conducted a study to investigate the role of health insurance plans on biosimilar adoption among commercially insured patients in the USA. Flexible and rigid health plans may exhibit differing biosimilar coverage due to variations in cost considerations, formulary design, and provider networks. Objective: To identify the characteristics of switchers and biosimilar initiators for six biologic-biosimilar pairs. Methods: Using claims data from 2015 to 2019, we implement sequential regression models to assess the role of health plans on biosimilars adoption. Findings: We found that low-flexibility plans, such as Health Maintenance Organization (HMOs) and Exclusive Provider Organization (EPOs), are more likely to have patients who are switchers and/or biosimilar initiators. Conclusion: Our findings highlight the importance of health insurance plan design in promoting biosimilar uptake.